Colossal Biosciences, the $10.32 billion startup trying to bring back the woolly mammoth, just partnered with the U.S. government to genetically catalog every endangered species in America. The federal contribution to that effort is exactly zero dollars. For a company still pre-revenue on its headline product, that is not a charity move. It is one of the cleaner pieces of business positioning you will see this year.
On June 25, 2026, the Department of the Interior and the U.S. Fish and Wildlife Service (FWS) announced a memorandum of understanding with Colossal to build the “BioVault,” a genomic and biobanking archive covering more than 2,300 threatened and endangered plant and animal species protected under the Endangered Species Act. Colossal will collect, sequence, and cryopreserve living cells, reproductive tissue, and DNA, then deposit the resulting reference genomes into open-access repositories for free.
Read the fine print and the story sharpens. The MOU does not obligate the federal government to spend a cent. Colossal has said it will fund the build itself, to the tune of tens of millions of dollars. So a heavily funded private company is volunteering to spend its own money on a national public service and then give the data away. The interesting question for any founder or operator is not “why save the species.” It is “what does Colossal actually buy with that spend.”
What the BioVault deal actually is
The Colossal-FWS BioVault. A non-binding partnership (memorandum of understanding) in which Colossal Biosciences preserves the genetic material of every U.S. Endangered Species Act-listed organism in a cryogenic biobank and publishes the sequenced genomes openly. No federal funding is attached. Any future work involving government money, property, or services would require separate agreements. Colossal runs the effort through its nonprofit arm, the Colossal Foundation.
The biobank itself is real and already running. Colossal stores cell lines, reproductive tissue, and DNA in liquid nitrogen at its Dallas headquarters, with roughly 200 species banked so far. The FWS deal scales that ambition from a corporate side project to a national reference library, the genetic equivalent of the Svalbard Global Seed Vault, which is exactly the comparison CEO Ben Lamm reached for in the announcement.
| The deal in numbers | |
|---|---|
| Announced | June 25, 2026 |
| Counterparties | Colossal Biosciences and U.S. Fish and Wildlife Service |
| Species targeted | More than 2,300 ESA-listed |
| Federal funding committed | $0 |
| Colossal’s projected spend | Tens of millions of dollars |
| Data access | Open-access, free to global researchers |
| Structure | Non-binding MOU via the Colossal Foundation |
The business question hiding behind the headline
Here is the tension that makes this a business story and not just a science story. Colossal is valued at $10.32 billion. It became Texas’s first decacorn in January 2025 and has raised a $320 million Series C across two tranches, led by TWG Global and later USIT, on top of earlier rounds that push total funding past half a billion dollars. And yet the flagship product, a living mammoth, is not expected until a calf targeted for late 2028. De-extinction revenue to date is none.
That gap between a multibillion-dollar price tag and a product that does not exist yet is the entire game. The valuation is not paid for by cash flow. It is paid for by belief, and belief runs on milestones, headlines, and credibility. This is the same pattern we flagged in the biggest pre-revenue venture rounds: investors in capital-heavy, long-timeline categories are buying expected future market share, not current earnings. The job of a company in that position is to keep the narrative compounding faster than the burn.
A zero-dollar federal partnership is narrative rocket fuel.
Why a free deal is a good deal
Strip away the press-release language and Colossal is buying four things with its own money, none of which show up as a line item.
| What Colossal “buys” | Why it matters to the valuation |
|---|---|
| Federal legitimacy | A government stamp reframes a flashy dire-wolf company as serious national infrastructure |
| Default-platform position | Becoming the system of record for U.S. conservation genomics is a moat competitors cannot easily rebuild |
| A proprietary capability layer | The genomes are open, but the sequencing, biobanking, and assisted-reproduction tooling stay Colossal’s |
| Optionality | Positions Colossal for future markets like biodiversity credits and paid genetic-rescue work |
If that “buy legitimacy and a foothold, not revenue” logic sounds familiar, it should. It is structurally the same move as Google’s $75 million investment in A24, where the point was a credible foothold in a skeptical industry rather than a near-term return. Give away the visible asset (the data, the storyboards), keep the rails and the relationship. Open-sourcing the output while owning the infrastructure is the oldest platform play in tech, now applied to wildlife DNA.
Where the money actually comes from
The de-extinction headlines are the marketing budget. The business sits in the spin-outs and acquisitions, a “platform alongside product” structure that shows up across the fastest-growing biotech startups.
| Revenue or value engine | Status |
|---|---|
| Form Bio (computational biology spin-out) | Reported seven-figure ARR |
| Breaking (plastic-degrading microbes) | Raised $10.5M seed |
| ViaGen Pets and Equine (acquired Nov 2025) | Operating animal-cloning business with real revenue |
| Technology licensing | Gene-editing and reproductive tech to third parties |
| Artificial womb and fertility tech | Future spin-out, large adjacent market |
| Biodiversity credits | Speculative future market, not yet live |
Seen this way, the FWS deal is not the business. It is the thing that keeps the business fundable until the real revenue lines mature. The mammoth gets the magazine covers; ViaGen quietly clones your dog for money.
The skeptic’s case
Be fair to the bear argument, because it is not weak.
The whole structure depends on the narrative holding. A company spending tens of millions to give data away has converted a corporate asset into a public good, which is generous right up until you remember that the spend is only justified by a valuation that itself depends on the goodwill the spend generates. That is a flywheel, and flywheels can run in reverse. If the 2028 mammoth slips, if the dire-wolf “de-extinction” gets reframed by scientists as gene-edited gray wolves rather than a resurrection, or if the next funding environment turns cold, the same milestones that pumped the valuation can deflate it.
There is also a genuine conservation critique worth noting plainly: frozen cells do not protect habitat. A genomic backup is a recovery tool, not a substitute for the wetlands, corridors, and protections a species needs to survive in the first place. That critique does not hurt Colossal’s business, but operators should not confuse a brilliant positioning move with a solved conservation problem. The deal also lands while federal endangered-species rules are themselves being reworked, which adds policy uncertainty around how much the partnership will ultimately be allowed to do.
What founders and operators should take from this
The transferable lesson is not “do free government deals.” It is sharper than that.
When your valuation is built on belief rather than cash flow, credibility-building spend can be more valuable than revenue. Colossal understood that a federal partnership, even one worth nothing on the P&L, moves the only number that currently matters, which is the next round’s valuation. Founders in pre-revenue, long-timeline categories should ask which “unprofitable” moves actually buy the narrative their capital depends on. Sometimes the best line item is the one that never appears on the income statement.
Frequently asked questions
Is the U.S. government paying Colossal Biosciences for the BioVault?
No. The June 2026 memorandum of understanding does not obligate any federal funding. Colossal has said it will spend tens of millions of dollars of its own money. Any future work involving federal funds, services, or property would require separate agreements.
How is Colossal Biosciences valued at over $10 billion if it has no de-extinction revenue?
Its $10.32 billion valuation reflects investor bets on the future commercial potential of its gene-editing, biobanking, and reproductive technologies, plus revenue from spin-outs like Form Bio and its ViaGen animal-cloning acquisition, rather than current de-extinction sales. Its first mammoth calf is targeted for late 2028.
What does Colossal get out of giving the genome data away for free?
Federal legitimacy, a default position as the system of record for U.S. conservation genomics, control of the underlying sequencing and biobanking infrastructure, and optionality on future markets such as biodiversity credits and paid genetic-rescue work.
How many species does the BioVault cover?
More than 2,300 plant and animal species listed under the U.S. Endangered Species Act.
Who founded Colossal Biosciences?
It was founded in 2021 by entrepreneur Ben Lamm and Harvard geneticist George Church.
The Business Model Analyst Take
The fastest way to misread this deal is to score it on the income statement, where it reads as a multimillion-dollar giveaway. Score it on the cap table instead and it is one of the cheapest ways Colossal could possibly defend a $10.32 billion valuation. A federal partnership converts “the dire-wolf company” into “the national genomic-conservation utility,” and it does so without diluting equity or burning a meaningful share of the war chest. The genomes go to the public; the legitimacy, the infrastructure, and the relationship stay with Colossal. That is not philanthropy with a press release attached. It is positioning with a conservation mission attached, and the mission is real enough that the positioning works. The risk is the same one stalking every belief-funded business right now: the narrative has to keep paying for itself. For roughly the price of a Super Bowl ad spread over a few years, Colossal just bought the most durable kind of credibility there is. The mammoth still has to show up in 2028. Until then, the company has found a way to make doing visible good look exactly like good business, because here it is both.
